This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Proton pump inhibitors (PPIs) and hypomagnesaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • prolonged use of proton pump inhibitors (PPIs) has been associated with case reports of hypomagnesaemia

    • some cases occurred after 3 months of PPI therapy, but most occurred after 1 year of treatment
      • serious manifestations of hypomagnesaemia - fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia - can occur, but they may begin insidiously and be overlooked. In most case reports, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI

  • healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment, especially in those who will take a PPI concomitantly with digoxin or drugs that may cause hypomagnesaemia (eg, diuretics)

The MHRA advise that healthcare professionals should:

  • consider measurement of magnesium levels before starting PPI treatment and periodically during prolonged treatment, especially in those who will take a PPI concomitantly with digoxin or drugs that may cause hypomagnesaemia (eg, diuretics)
  • take into account any use of PPIs obtained over-the-counter

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page